




Dana-Farber
Cancer Institute



LncRNAs: the Dark that Matters

“Genome-Wide CRISPR *interference* Screen Identifies RNA Regulator of Lipogenesis (RROL) as a Leading LncRNA Dependency in Multiple Myeloma”

18th International Myeloma Workshop
Eugenio Morelli, M.D.
Munshi Lab




Disclosures

- *I do not have conflicts of interest.*

LncRNAs & Myeloma: a new source of genetic vulnerabilities?


Rationale of the study

LncRNA are dysregulated in MM



- Up (n=474)
- Dn (n=395)

LncRNA signatures can predict the clinical outcome of MM patients



Samur M, Leukemia, 2018

To explore LncRNA Dependency in Multiple Myeloma

Systematic mapping
of
lncRNA dependencies




Molecular mechanisms
&
Regulatory functions




Therapeutic
targeting

CRISPR *interference* (CRISPRi) viability screen identifies MIR17HG as a leading lncRNA dependency in MM

Screening Approach




Ranked Analysis





**To Characterize
MIR17HG Dependency
in MM**

RNA Regulator of Lipogenesis (RROL) mediates MM dependency to MIR17HG



1. RROL depletion + Overexpression of pri-mir-17-92 = **NO RESCUE**



Pri-mir-17-92



2. RROL depletion + Knockout of DROSHA = **NO RESCUE**




RROL promotes MYC transcriptional activity via direct RNA-protein interaction

RROL affects MYC transcriptional activity


Upstream Reg. Analysis (Ingenuity)

(Analysis of gene expression after RROL depletion)




**MIR17HG cooperates with MYC in tumorigenesis...
...via RROL?**



RNA Protein Pull-down



RNA Immunoprecipitation




RNA Yeast-3-Hybrid




RROL provides chromatin scaffold for MYC occupancy at the ACC1 promoter

RROL Top Targets
(30)




FOCUS on ACC1


Top Target of RROL



Top Target of MYC



Vulnerability in MM





RROL provides chromatin scaffold for MYC occupancy at the ACC1 promoter

RROL Top Targets
(30)


FOCUS on ACC1

RROL-MYC
Coregulated
Targets
(22)



Chromatin Isolation by RNA Purification
(ChIRP)



RNA FISH / IF




MYC ChIP-qPCR
w/o RROL depletion




RROL assembles a MYC-WDR82 complex at the ACC1 promoter

Proximity-dependent biotin identification (BioID) w/o RROL depletion




MYC Co-IP/MS w/o RROL depletion




WDR82 promotes MYC occupancy at the ACC1 promoter


MYC ChIP-qPCR w/o WDR82 depletion




WDR82 occupy the ACC1 promoter in RROL-dependent manner





RNA Yeast-3-Hybrid



WDR82 ChIP-qPCR w/o RROL depletion




The RROL-ACC1 transcriptional axis promotes *de novo* lipogenesis in MM cells




**RNA Regulator of Lipogenesis
(RROL)**

Proposed model of RROL Dependency in MM




RROL is Therapeutically Actionable using Lipid-conjugated ASOs

Development of Therapeutic ASOs




- Multistep ASO screen (>70 molecules)
- Derived 2 leading candidates
 - ❖ Steric-Blocker (SB)
 - ❖ Degradator or gapmer (G)
- Lipid-conjugation for improved PK


Subcutaneous MM xenograft



BLI-based MM xenograft



Take home message



- LncRNA are a relevant source of genetic vulnerabilities to be molecularly, functionally and therapeutically explored.
- RROL is a leading lncRNA dependency in MM.
- RROL is susceptible to therapeutic intervention.

Acknowledgements

Munshi Lab

N. Munshi

M. Fulciniti

M. Kemal Samur

A. Aktas Samur

S. Talluri

M. Shammas

All lab members

Anderson Lab

K. Anderson

A. Gullà

Y. Tai

T. Hideshima

D. Chauhan

G. Bianchi

M. Johnstone

All lab members

Loda Lab

M. Loda

C. Ribeiro

Lin Lab

C. Lin

W.D. Park

Young Lab

R. Young

J. Henninger

Tassone Lab

P. Tassone

N. Amodio

C. Federico

F. Scionti

Novina Lab

C. Novina

L. Wert Lamas

Penn Lab

L. Penn

Neri Lab

A. Neri

K. Todoerti

S. Gryaznov

All our patients!!!



Miracles for Myeloma



INTERNATIONAL
MYELOMA
FOUNDATION



Specialized Program of Research
Excellence (SPORE) in
Multiple Myeloma



Dana-Farber
Cancer Institute